An appellate court panel ruled Tuesday that drug manufacturers may not impose 340B rebates without approval from the U.S. Department of Health and Human Services (HHS). | The ruling upheld a previous decision that pharma companies cannot impose rebates without HHS Secretary approval.
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
After years of investigation, the outgoing chairman of the Senate Health, Education, Labor and Pensions Committee has released…
Eli Lilly and Company said Monday evening that it will soon end 340B discount pricing for some of the hospitals that have not met…
Several academic and nonprofit health systems have filed lawsuits against CVS Health, accusing the company and its subsidiaries…
Outpatient drug purchases under the 340B Drug Pricing Program crossed the $100 billion mark across 2025, a roughly 23% increase…
The Trump administration has proposed a "sweeping crackdown" on Medicaid payments that it says have significantly inflated costs…
The Trump administration has reaffirmed its pursuit of a sweeping Medicare funding block on providers of pediatric…
